Are elderly patients poor candidates for pegylated interferon plus ribavirin in the treatment of chronic hepatitis C?

J Am Geriatr Soc. 2006 Mar;54(3):549-50. doi: 10.1111/j.1532-5415.2006.00643_4.x.
No abstract available

Publication types

  • Comparative Study
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Age Factors
  • Aged
  • Antiviral Agents / therapeutic use*
  • Drug Therapy, Combination
  • Female
  • Hepatitis C, Chronic / drug therapy*
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / therapeutic use*
  • Male
  • Middle Aged
  • Polyethylene Glycols
  • Recombinant Proteins
  • Ribavirin / therapeutic use*
  • Risk Factors
  • Treatment Outcome

Substances

  • Antiviral Agents
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins
  • Polyethylene Glycols
  • Ribavirin
  • peginterferon alfa-2b